Muvz is formulated with two botanicals—Vitex negundo and Zingiber officinale—known for their analgesic, anti-inflammatory and antioxidant properties. Muvz became an OmniActive product following the 2024 acquisition of Enovate Biolife and is well-positioned to meet the demand of the global joint health market which sits at more than $11.5 billion, according to the company.
Abhijeet Morde, senior director of in vitro biology, animal studies and clinicals at OmniActive, said the study results “align with previous studies, further reinforcing Muvz as a natural ingredient solution for supporting mobility through joint and low-back comfort support as well as flexibility in physically active individuals.”
Global burden
The musculoskeletal system is dependent on interactions between various types of tissues. As the body ages along with the strain of repeated movements, there are degenerative changes to articular cartilage and intervertebral discs, and this can lead to joint discomfort.
Approximately 1.71 billion people globally are impacted by conditions like osteoarthritis, neck pain, low back pain and injuries, according to 2019 Global Burden of Disease data. Of these, low back pain is considered the main contributor to the overall musculoskeletal burden. According to the World Health Organization, one in 13 people experience low back pain.
“Low back discomfort also serves as the primary cause for premature departure from the workforce,” the study’s researchers noted. “The societal ramifications of early retirement, including direct healthcare expenses and indirect costs such as absenteeism or reduced productivity are significant.”
They noted that while current interventions on the market focus on symptom relief and do not target pathology, some dietary ingredients and supplements show promising results in addressing joint health.
Among these, Vitex negundo (V. negundo) has been recognized in Ayurveda as a potent botanical with strong anti-inflammatory and analgesic properties and possesses pain-suppressing activity.
Zingiber officinale (Ginger) rhizome is a widely recognized Asian spice with traditional use as an anti-nausea, anti-inflammatory and analgesic agent.
Study details
Building on previous research including a knee joint discomfort study, the current study investigated the dose-response efficacy and safety of a daily dose of Muvz at 400 mg (high-dose) and 200 mg (low-dose) for three months.
Participants included 157 adults between the ages of 40 and 60 years with knee/low back pain discomfort who were randomly assigned to either an experimental or placebo group.
“The study found that supplementation with Muvz at both doses significantly improved musculoskeletal health questionnaire scores starting at day 30, supported joint and low-back comfort, reduced discomfort after physical activity and enhanced both active and passive flexion range of motion by day 90,” the researchers reported.
“These results suggest that both doses are effective, but further studies are needed to determine if there is a threshold beyond which additional supplementation does not provide added benefits. Understanding Muvz’s bioavailability will be an important next step in optimizing its dosing strategy.”
OmniActive plans to build upon these findings to incorporate more objective measures to further validate Muvz’s efficacy, including assessing inflammatory biomarkers to better understand the underlying mechanisms driving the observed improvements.